The overall goal of the proposed study is the discovery and preclinical validation of novel targets associated with molecular processes that lead to cognitive decline, the primary outcome of most AD trials. The recent NIA Alzheimer's Disease Research Summit 2012: Path to Treatment and Prevention that led to the RFA to which we are responding, made a number of recommendations which motivated the strategy adopted in the proposed study. Our proposal brings together an exceptionally strong and unique multi-disciplinary team with the relevant skills needed to achieve our overall goal.
In Aim 1, we take a systems biology approach to mine a truly unique set of deep clinical, paraclinical, pathologic, genomic, epigenomic, and transcriptomic data assembled from frozen dorsolateral prefrontal cortex brain tissue of 1000 subjects from two cohort studies of aging and dementia, the Religious Order Study and the Memory and Aging Project, in conjunction with other publicly available functional datasets. These unique data provide an excellent substrate for the identification and nomination of molecular targets for drug discovery. Target discovery is coupled with a flexible translational strategy that first validates targets by a targeted proteomic study of brain tissue from the same region and subjects in Aim 2.
In Aim 3, an RNA interference (RNAi) and overexpression functional validation study in cultured human neurons and astrocytes is executed in parallel in Aim 3. Finally, these data come together in Aim 4 which performs high throughput small molecule screens on neurons and astrocytes derived from induced pluripotent stem cells (iPSC) on the most promising targets. Our proposal is ambitious but realistic: it reflects the deployment of cutting-edge approaches with a practical mindset in which redundancies have been carefully considered to mitigate risk and ensure the delivery of data, network models and lead compounds. The proposed study will discover and validate novel targets associated with molecular processes that lead to cognitive decline, and it will demonstrate the druggability of one or more targets, setting the stage for clinical trials with new and novel approaches to the prevention and treatment of AD.
The prevention and treatment of AD is a major public health priority. However, novel therapeutic targets are urgently needed. The proposed study will leverage deep phenotypic and multi-level -omics data to identify novel therapeutic targets, functionally validate and subsequently demonstrate the druggability of a number of selected targets, thereby filling an important gap between the new generation of -omics technology and the identification of novel and druggable targets to move to preclinical or clinical trials.
|Guo, Caiwei; Jeong, Hyun-Hwan; Hsieh, Yi-Chen et al. (2018) Tau Activates Transposable Elements in Alzheimer's Disease. Cell Rep 23:2874-2880|
|Bennett, Rachel E; Robbins, Ashley B; Hu, Miwei et al. (2018) Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A 115:E1289-E1298|
|Tasaki, Shinya; Gaiteri, Chris; Mostafavi, Sara et al. (2018) Multi-omic Directed Networks Describe Features of Gene Regulation in Aged Brains and Expand the Set of Genes Driving Cognitive Decline. Front Genet 9:294|
|De Jager, Philip L; Ma, Yiyi; McCabe, Cristin et al. (2018) A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Sci Data 5:180142|
|Wang, Xulong; Philip, Vivek M; Ananda, Guruprasad et al. (2018) A Bayesian Framework for Generalized Linear Mixed Modeling Identifies New Candidate Loci for Late-Onset Alzheimer's Disease. Genetics 209:51-64|
|Chibnik, L B; White, C C; Mukherjee, S et al. (2018) Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies. Mol Psychiatry 23:1521-1529|
|Yu, Lei; Petyuk, Vladislav A; Gaiteri, Chris et al. (2018) Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia. Ann Neurol 84:78-88|
|Sekiya, Michiko; Wang, Minghui; Fujisaki, Naoki et al. (2018) Integrated biology approach reveals molecular and pathological interactions among Alzheimer's A?42, Tau, TREM2, and TYROBP in Drosophila models. Genome Med 10:26|
|Dobbyn, Amanda; Huckins, Laura M; Boocock, James et al. (2018) Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and Co-localization with Schizophrenia GWAS. Am J Hum Genet 102:1169-1184|
|Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872|
Showing the most recent 10 out of 40 publications